Ionis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data
- Pfizer, banks lead Wall Street lower; presidential debate eyed
- Unusual 11 Mid-Day Movers 9/26: (ARRY) (SMMT) (ACTA) Higher; (PTIE) (DRRX) (SALE) Lower
- CBOE Holdings (CBOE) to Acquire Bats Global Markets (BATS) in ~$3.2B Deal
- LANXESS to Acquire Chemtura (CHMT) in ~$2.5B Deal
- Pfizer (PFE) Won't Pursue Split
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), announced the publication in The Lancet of key clinical results of two randomized, controlled studies of IONIS-APO(a)Rx and IONIS-APO(a)-LRx, the company's Lp(a)-lowering drugs designed to treat cardiovascular disease and aortic valve stenosis. Lipoprotein(a), or Lp(a), is an independent, causal, genetic risk factor for cardiovascular disease and aortic valve narrowing (stenosis). In these studies, substantial Lp(a) reductions of up to 99% were noted, regardless of starting Lp(a) levels. In addition, reductions in low-density lipoprotein-cholesterol - (LDL-C) and pro-inflammatory oxidized phospholipids were observed, as well as a decrease in the inflammatory effects of white blood cells, which can initiate and accelerate cardiovascular disease.
"Patients with Lp(a)-driven cardiovascular disease have no viable therapeutic options today for significantly lowering their Lp(a) to a level where risk can be minimal. And, since a patient's Lp(a) level is genetically determined, changes in lifestyle, such as diet and exercise, have minimal, if any, impact," said Sotirios Tsimikas, M.D., senior author of the paper, vice president of clinical development at Ionis Pharmaceuticals and professor of medicine and director of vascular medicine at the University of California, San Diego. "The results from these studies show, for the first time, a new therapy that can substantially reduce Lp(a), regardless of a patient's starting Lp(a) level."
The paper titled "Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials" (Viney et al., The Lancet) documents the results of two clinical studies testing the safety, tolerability and efficacy of antisense drugs designed to lower elevated Lp(a) levels. The published clinical findings are a result of a partnership with the Sulpizio Cardiovascular Center at the University of California San Diego School of Medicine.
The IONIS-APO(a)Rx study is the first randomized clinical study to evaluate a specific Lp(a)-lowering therapy in patients with or at high risk for cardiovascular disease with elevated Lp(a) levels. Treatment with IONIS-APO(a)Rx in patients with high (50-175 mg/dL or 125-437 nmol/L) or very high (>175 mg/dL or >437 nmol/L) Lp(a) levels resulted in a mean reduction in Lp(a) of 67-72%, with up to a 94% reduction. In addition, a significant reduction was noted in pro-inflammatory oxidized phospholipids and the inflammatory effects of monocytes, as well LDL-C.
The IONIS-APO(a)-LRx trial studied an optimized and more potent LICA drug that contains a GalNAc moiety that enhances delivery of drug to hepatocytes where Lp(a) is made and assembled. In this first-in-man study, multiple doses of IONIS-APO(a)-LRx resulted in mean reductions in Lp(a) of 66% in the 10 mg group, 80% in the 20 mg group, and 92% in the 40 mg group, and up to a 99% reduction. In these short-term studies, the drug was well tolerated. No side effects were noted in any laboratory tests and there were no injection site reactions.
"IONIS-APO(a)-LRx has shown more than 30-fold greater potency compared to IONIS-APO(a)Rx. This means that with much lower doses of IONIS-APO(a)-LRx we can achieve similar or better efficacy than IONIS-APO(a)Rx and monthly or even less frequent dosing may be feasible," said Richard Geary, Ph.D., senior vice president of development at Ionis Pharmaceuticals. "IONIS-APO(a)-LRx has the potential to eliminate nearly all Lp(a)-mediated risk by normalizing Lp(a) levels in almost all patients and reducing oxidized phospholipid levels and monocyte inflammation. It has also demonstrated that it can reduce LDL-cholesterol on top of current therapies. Furthermore, Ionis' LICA technology shows unprecedented potency and tolerability and represents the transformative potential for antisense drugs, both in cardiovascular and in non-cardiovascular arenas."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xinyuan Real Estate (XIN) Appoints New CFO
- Janssen Announces FDA Approval of STELARA as Crohn's Disease Treatment
- Cantel Medical (CMN) Acquires Vantage Endoscopy's Endoscopy Reprocessing Assets
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!